Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP: BAYRY )

6.800 +0.030 (+0.44%)
Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Aktienges ADR

< Previous 1 2 3 4 5 6 Next >
Ring The Register; Plus, Where To Park Your Profits
Sometimes an investment works out a lot quicker than expected. That’s the case with my July 2022 pick, Freeport-McMoRan Inc., the fourth-largest copper mining company in the world. 
Via Talk Markets
Bayer Bolsters Its Position In Digital Medical Imaging With Acquisition Of UK-Based Firm
Via Benzinga
FAA Technology Glitch Hits US Flights Operations, Coca-Cola & PepsiCo Under FTC Probe, Rivian Hit By Mass Executive Exodus: Today's Top Stories
Reuters 
Via Benzinga
Activist Investor Builds Stake In Bayer, Pushes Breakup
Activist investor Bluebell Capital Partners has built a stake in Bayer AG (OTC: BAYRY) (OTC: BAYZF) and is pushing it to split up.  
Via Benzinga
Key Marijuana Executive Changes: Who Will Lead MariMed After CEO's Passing? MJBiz CEO Steps Down
MJBiz CEO To Step Down Marijuana Business Daily's Chris Walsh will step down as CEO in January. 
Via Benzinga
Bayer: Aspirin To Crop Protection
Pharmaceutical drugs account for 41% of Bayer's revenues and include Xarelto, Eylea, Mirena, Kogenate and Nexavar. Its OTC product lineup is filled with household names like Aleve, Alka Seltzer,... 
Via Talk Markets
Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death
Via Benzinga
Current Report: Bayer AG
By my dogcatcher ideal, this may be a prime time to buy Bayer AG shares based on their dividends for the coming year 2022-23. 
Via Talk Markets
Ionis Regains Rights To Thrombosis Candidate From Bayer
Via Benzinga
Can Acquisitions and Partnerships Take Ginkgo Bioworks (DNA) Stock Higher?
It seems that Ginkgo Bioworks is announcing a new acquisition or collaboration every day this month, putting DNA stock in focus. 
Via InvestorPlace
What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today?
AVEO stock jumped on the news that LG Chem will pay $15/share for Aveo Oncology and make it the centerpiece of a new oncology division. 
Via InvestorPlace
Elon Musk Renews Twitter's Buyout Proposal, Apple Suppliers Working On Cutting China Reliance, E-Cigarette Maker Considers Bankruptcy: Top Stories Wednesday, Oct. 5
Wall Street Journal 
Via Benzinga
Bayer, Exscientia Part Ways On Artificial Intelligence Collaboration
Via Benzinga
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
Via Benzinga
Roundup Weedkiller Maker Bayer Won Five Consecutive Cases, Shifting Momentum In Bayer's Favor
Bayer AG (OTC: BAYRY) won five jury verdicts in a row in trials that contended its Roundup weed killer caused non-Hodgkin lymphoma. The company battles the remaining cases targeting its Roundup... 
Via Benzinga
Top Financial Stories Wednesday, September 14: Multiple Antitrust Setbacks For Google, Bitcoin Crashes, Visa Finds New Gun Control System Ineffective And More...
Reuters 
Via Benzinga
After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report
Via Benzinga
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
Via Benzinga
Deere Invests Billions In Self-Driving Tractors, Smart Crop Sprayers: Report
Via Benzinga
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
Via Benzinga
7 Stocks Under $15 to Buy and Hold Forever
For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul. 
Via InvestorPlace
Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops
The companies hoped to reduce the risk of myriad complications for at-risk patients. 
Via Investor's Business Daily
This Biotech Says Stem Cells May Be Key To Freeing 65 Million Americans From Chronic Back Pain, Painkiller Dependence
BioRestorative Therapies Inc. (NASDAQ: BRTX), a stem cell-focused biotech, says it wants to shift the paradigm of how doctors treat chronic pain in hopes of giving patients an option that’s effective,... 
Via Benzinga
Why Is Ginkgo Bioworks (DNA) Stock in the Spotlight Today?
DNA stock is down even while Ginkgo Bioworks prepares to purchase a biotech business and a large research and development site. 
Via InvestorPlace
Science Wednesday: 'Silent Spring' At 60; Preserved Baby Mammoth Found In Yukon; Filling Medical Imaging, Nursing Shortages
(This marks the first installment of Benzinga’s new weekly series Science Wednesday, which provides an overview of news and milestones within the sciences.) 
Via Benzinga
BWXT Medical, Bayer Ink Commercial Agreement For Actinium-225 Based Products
Via Benzinga
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. 
Via Benzinga
7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend
These seven blue-chip stocks are trading at relative bargains and they can all be added to your portfolio for less than $250. 
Via InvestorPlace
Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off
Via Benzinga
Three Stocks To Buy In This Bear Market
There’s a silver lining to the current bear market. It’s created great buying opportunities. 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.